The emerging role of microglia in the development and therapy of multiple sclerosis.

IF 4.8 2区医学 Q2 IMMUNOLOGY

International immunopharmacology Pub Date : 2024-12-25 Epub Date: 2024-10-30 DOI:10.1016/j.intimp.2024.113476

Yunrong Nan, Shuting Ni, Mei Liu, Kaili Hu

引用次数: 0

Abstract

Microglia are innate immune cells that maintain homeostasis of the central nervous system (CNS) and affect various neurodegenerative diseases, especially multiple sclerosis (MS). MS is an autoimmune disease of the CNS characterized by persistent inflammation, diffuse axonal damage, and microglia activation. Recent studies have shown that microglia are extremely related to the pathological state of MS and play an important role in the development of MS. This article reviews the multiple roles of microglia in the progression of MS, including the regulatory role of microglia in inflammation, remyelination, oxidative stress, the influence of phagocytosis and antigen-presenting capacity of microglia, and the recent progress by using microglia as a target for MS therapy. Microglia modulation may be a potential way for better MS therapy.

查看原文本刊更多论文

小胶质细胞在多发性硬化症的发展和治疗中的新作用。

小胶质细胞是一种先天性免疫细胞，能维持中枢神经系统（CNS）的平衡，并影响各种神经退行性疾病，尤其是多发性硬化症（MS）。多发性硬化症是一种中枢神经系统自身免疫性疾病，其特征是持续性炎症、弥漫性轴突损伤和小胶质细胞活化。最近的研究表明，小胶质细胞与多发性硬化症的病理状态极为相关，并在多发性硬化症的发展过程中扮演着重要角色。本文综述了小胶质细胞在多发性硬化症进展过程中的多重作用，包括小胶质细胞在炎症、髓鞘再形成、氧化应激中的调节作用，小胶质细胞吞噬和抗原递呈能力的影响，以及将小胶质细胞作为多发性硬化症治疗靶点的最新进展。调节小胶质细胞可能是更好地治疗多发性硬化症的潜在方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International immunopharmacology 医学-免疫学

CiteScore

8.40

自引率

3.60%

发文量

935

审稿时长

53 days

期刊介绍： International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome. The subject material appropriate for submission includes: • Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders. • Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state. • Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses. • Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action. • Agents that activate genes or modify transcription and translation within the immune response. • Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active. • Production, function and regulation of cytokines and their receptors. • Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.